RNS Number : 5475V
OptiBiotix Health PLC
04 December 2019

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Appointment of European Sales Leader for ProBiotix Health Ltd

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the appointment of Mikkel Hvid-Hansen as European Sales Leader of its wholly-owned subsidiary, ProBiotix Health Ltd ("ProBiotix").

ProBiotix was created to develop science based healthy bacteria called probiotics to reduce cardiovascular risk. Independent clinical studies have shown its LP_{LDL}® probiotic can reduce key cardiovascular risk markers such as total cholesterol, LDL (bad) cholesterol, and blood pressure by up to 36.7%, 13.9% and 5.1% respectively. Since launching its CholBiome® products containing LP_{LDL}® in May 2017, ProBiotix has signed over 23 agreements and its products are now commercialised in 23 countries. LP_{LDL}® was designated Generally Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in the United States in February 2019, which extends its applications from use as a supplement to use as a functional ingredient in a wide range of food, dairy, and beverage products in the USA.

Mikkel is joining ProBiotix from a position as International Sales Manager from Cell Biotech Int. ("Cell Biotech"), a Korean probiotic company selling bulk ingredients and finished products internationally. Prior to joining Cell Biotech, Mikkel spent six years as International Sales Manager at Bifodan where he had responsibility for the sales of several probiotic OTC drugs. Previously, Mikkel also worked for Lallemand, the world's third largest probiotic company (1998-2006) and Eraco (1995-1998). Mikkel brings extensive experience of commercialising probiotics products and technologies, a wide network of industry contacts, and a strong track record of rapidly growing sales.

Mikkel will be based in Denmark to support existing sales in Europe and extend the market opportunities for LP_{LDL}® within the European probiotic supplement, food, and dairy markets.

Steve Prescott, CEO of ProBiotix Health Ltd., commented: "*Mikkel's experience and track record of launching new products and growing sales within Europe brings*

over 20 years of commercial and probiotic industry expertise to OptiBiotix's wholly owned probiotic subsidiary, ProBiotix Health Ltd. His network of contacts provides access to key customers which we hope will continue to drive revenue growth of LP_{LDL}® in supplement, food and pharmaceutical products around the world. We are delighted that Mikkel has joined ProBiotix Health at such an exciting stage of its development transforming the company from R&D to commercial sales focused."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc — www.optibiotix.com
Stephen O'Hara, Chief Executive — *Contact via Walbrook below*

Cairn Financial Advisers LLP (NOMAD) — Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti

finnCap (Broker) — Tel: 020 7220 0500
Geoff Nash/ Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)

Walbrook PR Ltd — Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy — Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 25 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEXLFBKLFBFBV